Search results

4G Clinical is a global leader in randomisation and trial supply management and supply forecasting optimisation software for the life sciences industry, offering a fully cloud-based, 100% configurable solution using natural language processing to accelerate clinical trials.

Abbmira therapeutics is a Basel based biotech founded by experience scientists and entrepreneurs in September 2024. Abbmira develops first-in-class small molecules to fine-tune native immunity to treat difficult-to-treat cancers and chronic diseases.

ACM Biosciences AG is a subsidiary of ACM Biolabs PTE Ltd. Singapore. Its purpose is to internationalise its development activities. It leads all clinical and regulatory activities of its pipeline programs and coordinates business development discussions with potential partners.

Akceso Advisors: specialist pricing, reimbursement & market access advisor firm. For your buy/sell side 'Evidence-based Asset Valuation' and payer-relevant input into your development plan design. Akceso Advisors: Catalysts to patient access and pricing success. For better public health worldwide.

Allegria Therapeutics was founded in Basel in 2023. Pursuing a differentiated portfolio of proprietary therapeutic approaches around biological targets that selectively modulate mast cells, Allegria plans to redefine the treatment landscape for allergy and mast cell-mediated inflammatory diseases.

Amphilix AG is a Basel-based biotech developing next-generation radioligand therapies using a proprietary 3D linker platform and small-molecule ligands. Its clinical-stage lead AMX-0053 targets a protein for colorectal cancer and is ready for First-in-Human imaging. The company seeks CHF 9m Seed.

Amporin is developing a new class of small molecule amyloid pore inhibitors as the first potential acute oral drugs to stop and reverse the progression of deadly degenerative diseases. Our vision is to cure 6 major degenerative diseases with a simple pill, starting with Parkinson’s disease.

AMYRA is developing a unique enzyme combination for curative care of Celiac Disease and Non-Celiac Gluten Sensitivity (NCGS), which represent major public health issues. AMYRA’s products have the potential to establish the standard of care and majorly impact the lives of affected people.

Anaveon is a global clinical stage biopharmaceutical company that specializes in developing novel treatments for diseases with high unmet needs. Our team is driven to make this vision a reality: we are committed to transforming immunological insights into life-changing therapies.

As a health company, we envision empowering global well-being by pioneering biological solutions drawn from nature. Our mission: Unlock the full potential of exDNA across diverse indications. Our AND Technology Platform has the primary focus on controlling disease caused by pathogenic bacteria.

ANSEA is a global consulting firm enabling pharmaceuticals, biopharmaceuticals and medical device companies navigate through the complexities of healthcare systems across the world and helping bring their solutions to patients.

ARTBIO is a clinical-stage radiopharmaceutical company focused on developing a new class of alpha radioligand therapies (ARTs) to transform cancer treatment. ARTBIO's approach centers on utilizing the alpha-emitting isotope Pb212 to target cancer cells while minimizing damage to healthy tissues.

Artidis® is a pioneering clinical stage health technology company that aims to set the gold standard in tissue analysis and therapy optimization. Artidis focuses its efforts on solid tumors to enhance responses to chemo, immuno, and cell therapies, driving precision in cancer care.

Aukera builds a discovery engine that allows designing new classes of drugs to selectively target different branches of the mTOR pathway. The lead program selectively targets mTOR complex 1 to treat rare diseases, cancer, and neurodegenerative diseases, and uniquely addresses unmet medical needs.

AVEctivate supports pharma, biotech and diagnostic companies aiming to make a positive difference to patients, and health care providers by offering strategic consulting, project management and interim management. Believing that change is the only constant, we embrace the future as an opportunity.

Azafaros is a clinical-stage biotech company addressing rare genetic lysosomal storage disorders with oral small molecules, including nizubaglustat. Our focus is on developing disease-modifying therapies for patients with, among others, GM1 and GM2 gangliosidoses, and Niemann-Pick Type C disease.

Basel Biotech Consutling GmbH provides biotechs and mid-stage pharmas with support on financing and business development. The expertise is based on over 20 years experience in investments having worked as a pharma analyst, fund manager, investor relations and business development professional.

BeOne Medicines is a global oncology company developing innovative, affordable, and accessible cancer treatments worldwide. We expedite development of our diverse pipeline of novel therapeutics through strong internal capabilities and collaborations. Our 11,000 colleagues span six continents.

Immune response on a chip!

BiomedVC is a leading Swiss early-stage venture capital fund at the center of European biotech. We focus on finding great science and building promising startups to deliver better medicines for patients.

We are experts in obtaining funding for biomedical and healthcare innovations, as well as for ICT, eHealth and big data fields projects. We help leading researchers and companies secure financing for ambitious R&D projects, from early stage pre-clinical research up to clinical stage development.

Celonic is a “Pure Play” Biologics CDMO with a focus on CHO-based expression systems. Celonic is a pioneer in using next generation bioprocessing technologies and has a state-of-the-art Biologics Development Center in Switzerland, with clinical and commercial GMP manufacturing facilities in Germany.

Cerdia, headquartered in Basel, is a pioneer in cellulose acetate tow since 1912 and a global quality and innovation leader of filter tow for cigarette manufacture. We are developing innovative applications and processes that will define Cellulose Acetate as a sustainable raw material in the future.

Chinsiders is a boutique advisory firm for SME life sciences companies. We excel at driving the full lifecycle (BD, contracting, alliance management) of cross-border transactions (licensing, partnering, M&A, distribution) and managing in-house legal matters (corporate, IP, contracts, etc)

CRB is a leading design, construction and consulting firm serving life sciences companies globally since 1984. From small studies to execution of complex projects, we have the expertise to deliver solutions to our clients in the local pharmaceutical and biotechnology market.

CTC – The Life Science Career Network - We provide excellence in Life Science recruitment and the latest in skill development programmes. We enable careers in the Life Science industry and support our clients in engaging, retaining and developing the right talent at the time needed.

Curare specializes in translational and clinical pharmacology, increasing confidence in therapeutics translation from the bench to clinical proof of concept, and enhancing early stage decision-making.Expertise tailored to your needs, from small biotech to pharma.

EraCal Therapeutics Ltd. develops a oral-active anti-obesity drug, a first-in-class appetite suppressor. This new chemical entity emerged from EraCal’s drug discovery platform, which also forms the basis of a research collaboration with Novo Nordisk.

EsoCap AG is developing a unique targeted delivery platform technology for the treatment of patients with diseases of the esophagus. EsoCap recently successfully completed the double-blind, randomised, placebo-controlled Phase II ACESO study in the lead indication eosinophilic esophagitis (EoE).

FatiAbGen International is the Swiss subsidiary of FatiAbGen Co. Ltd., established in Korea in 2020. We engineer best in class antibodies tailored for multiple modalities such as ADCs and bi-specifics. We then develop targeted molecules to address high unmet need diseases in oncology and immunology.

FimmCyte is developing disease modifying therapies for chronic diseases through the direct elimination of diseased cells. FimmCyte has a pipeline of assets two of which are about to begin IND enabling studies, one for endometriosis and the second for organ fibrosis.

Biotech venture builder (VC)

FoRx Therapeutics is a recently incorporated privately-held company based in Basel, Switzerland. FoRx Therapeutics focuses on drugging key molecular targets involved in the DNA Replication Stress, as a new approach in the development of targeted anticancer drugs.

GANDA offers tailored G&A services to Life Sciences companies, providing fractional expertise in financial management and planning, human capital, and corporate finance, among others. Their deep industry experience ensures seamless integration without lengthy onboarding.

Genedata transforms biopharma data into intelligence by combining deep science, technology, and AI domain knowledge. From early discovery to the clinic, the Genedata Biopharma Platform digitalizes and automates complex data workflows, driving innovation and data-based decisions to maximize ROI.

Genevant brings world-class delivery platforms that include best-in-class lipid nanoparticle (LNP) technology and next generation ligand conjugate technology, the industry’s most robust and expansive LNP patent estate, decades of experience and expertise in nucleic acid drug development.

GenSearch is a global Human Resources services consultancy dedicated to the Life Sciences industries. Our many years' experience allows us to support companies in their different stages of growth - from small start-up's to large multinational players. Offices: Basel, Frankfurt, London, Paris

Biotech in the Autoimmune/Fibrosis Therapeutics Space.

Swiss-based Life Sciences consultancy and part of the athagoras Group. We enable European market access for pharma & biotech, combining strategy, evidence generation and HTA expertise, from valuation and trial design to reimbursement, JSC, JCA and pricing negotiations.

HGF GmbH is one of Europe’s largest firms of IP specialists. With a dynamic and forward-thinking growth strategy, the firm is one of the few to offer clients a fully integrated IP solution, with 25 offices throughout the UK, Ireland, the Netherlands, Germany, Switzerland, France, and Austria.

We offer a integrated service model in the special areas of corporate transactions, international and local accounting & reporting as well as tax, from start-up to IPO or sale. We focus on M&A and CFO services including interim management. https://hoffmann-partner.com/en/

ICON is a global provider of outsourced drug development services and offers a flexible partnership model for biotechs, acting as a fully externalised project development team. We offer a full range of clinical, consulting and commercial services.

IPS-Integrated Project Services, a Berkshire Hathaway company, is a global leader in developing innovative solutions for the consulting, architecture, engineering, project controls, procurement, construction management, and CQV of technically complex facilities in the life sciences industry.

Jacobs is a world leading consulting, design and construction firm. In Switzerland we have a strong focus on life science industries mainly serving pharmaceutical and biotechnology companies.

Our foundation supports the transfer of innovation from medical research to industry, in particular through young entrepreneurship in Switzerland. We invest in companies in Switzerland or abroad that are active in the field of life sciences. We value strong founding teams and high-quality science.

Kellerhals Carrard's highly specialized and interdisciplinary Life Sciences team is one of the strongest in Switzerland. We advise biotech and pharma clients of all sizes from startups to large multinationals on their most prominent and complex matters, both in Switzerland and abroad.

KVALITO is a strategic service partner and a global Life Science network for regulated industries, focusing on quality We empower businesses in the life science and healthcare industries with ATI, ML, AI, AR / VR, blockchain, big Data, cloud and robotics.

Landmark BioVentures AG, founded in 2021 and headquartered in Basel, Switzerland, is an integrated and agile biotech hub-and-spoke company. LBV takes a unique model focused on lean operations, smart capital allocation, and diversified nexus of 7 companies developing 10 first-in-class therapeutics.

Livinovea is a full-service provider and consultancy for life sciences, specializing in business, operational, and technical excellence. We help companies unlock their potential, identify untapped opportunities, and solve complex challenges, to achieve growth and measurable results.

Luminance Health is a premium life science consultancy providing personalized support across the entire value chain. We provide cross-functional strategic and hands-on support to develop, register, market and bring innovative products to market.

Macrogen Europe GmbH, Swiss branch of Macrogen Europe B.V. (Amsterdam), provides fast, reliable Sanger and NGS sequencing. All sequencing labs are based in Amsterdam and Seoul. We support research and clinical needs across Europe and Africa with advanced genomic and bioinformatics services.

Maxia Strategies specializes in supporting biotechs with regulatory affairs and project development expertise. We also support in registration and market access activities in the US, EU and Switzerland. We submit MAA act as a MAH, and support in distribution and licensing request in Switzerland.

metaLead is an early-stage life science spinout from the University of Zurich, supported by reputable investors, i.e., BaseLaunch. We aim to revolutionize the treatment landscape for metal-related diseases, starting with Wilson disease, leveraging our platform of novel, rationally designed peptides.

Mosanna is committed to improving patient outcomes and quality of life in high unmet need diseases, carefully selecting innovative medicines for further development. Our first goal is to bring an effective and well tolerated medicinal nasal spray to Metabolic Obstructive Sleep Apnea patients.

NBE-Therapeutics engages in the development of “next-generation”, antibody drug conjugates (ADCs) with the objective to develop first-in-class ADC product candidates until clinical proof-of-concept in patients. NBE Therapeutics is part of the Boehringer-Ingelheim group.

NegotiumBio supports pharmaceutical & biotech companies in executing outsourced manufacturing and also business development strategies across diverse modalities (small / large molecules, cell & gene therapies).

Noema Pharma is a clinical-stage biotech pioneering a portfolio of disease-transforming therapeutics for CNS-mediated conditions.

Novaremed AG, a privately held clinical-stage biopharmaceutical company, is innovating chronic pain management through the development of effective and safe treatment options as an alternative to opioids. HQ Basel (Switzerland); subsidiaries Novaremed Ltd (Israel) & Metys Pharmaceuticals (CH).

Novartis is a global healthcare company based in Switzerland that provides solutions to address the evolving needs of patients worldwide.

Nxera Pharma is a tech-driven biopharma company focused on specialty medicines for unmet needs in Japan and globally. With 30+ active programs in neurology, GI, immunology, metabolic, and rare diseases, Nxera employs 350+ people across Japan, the UK, Switzerland, and South Korea.

NXI Therapeutics is committed to creating tomorrow’s disruptive immunotherapies for T cell-mediated autoimmune diseases and transplantation by coronin 1 modulation. NXI’s unique approach enables an auto- & allo-selective immunomodulation that retains immunocompetence against infections and cancer.

OMNI Life Science GmbH is located in Basel, Switzerland. We are your local partner for solutions in cell-based assays and are dedicated to provide innovative solutions for research in life science.

Pall Biotech offers a blend of innovative traditional, single-use and continuous processing technologies and services to create scalable bioprocessing solutions. From concept through to design, validation and production, Pall leverages best-in class technologies for all bioprocessing applications. Pall (Schwe

Parexel is focused on the development of innovative new therapies to improve the world’s health. We do this by providing a suite of groundbreaking biopharmaceutical development services that help customers across the globe transform scientific discoveries into new treatments for patients. From clinical tria

We are a community of passionate project and engineering makers. We founded Peleven to make the investment and project life as easy and successful as possible for our customers from the pharmaceutical, biotechnological as well as chemical research and their industry.

As an independent pharma consulting company, we have supported pharma and biotech companies since 2007. With a team of more than 25 consultants, Qualified Persons and support staff, three offices and hundreds of pharma partners in over 30 countries worldwide, we are ready to solve your challenges.

Praed Pharmaceuticals is biopharmaceutical company founded by industry experts. Our mission is to deliver a next generation treatment for Crohn’s disease. We are developing a promising oral compound, cadazolid, for the treatment of Crohn’s disease.

Provectis Healthcare AG is a global healthcare company based in Basel and the commercial partner of choice to the innovative biopharma. We advance the innovation through launch, commercialization and brand building in Europe, Middle East and Asia.

Quant Biomarkers aims to revolutionize cardio-renal and metabolic health with AI-driven solutions and novel biomarkers. We are at the forefront of precision medicine and our goal is to integrate our products into routine clinical workflows spanning primary and speciality care and clinical trials.

Rhizen is Swiss HQ biotech focused on discovery & development of innovative, small molecule drugs for the treatment of cancer & inflammatory diseases. The company has demonstrated leadership of the PI3K space and has a deep pipeline of novel differentiated assets across various stages of development.

RhyGaze is a cutting-edge biotechnology company based in Basel, Switzerland, and Philadelphia, Pa., USA, focused on developing gene therapies for retinal diseases causing blindness and aims to restore vision and transform the lives of patients worldwide.

MEDICE has always developed and produced medicinal products almost exclusively at the Iserlohn site and concentrates in the prescription area on CNS, renal medicine and dialysis medicine. Salmon Pharma is the Swiss subsidiary of MEDICE.

SEAL Therapeutics develops an innovative gene therapy approach that overcomes the functional defects causing LAMA2-related muscular dystrophy. The approach involves AAV-based delivery of specifically designed artificial linker proteins to compensate for the missing laminin-alpha 2 in muscle fibers.

Selective mode antimicrobial resistance therapeutics Selmod is a startup with a mission dedicated to the development of disruptive antibacterial and antifungal therapies needed to address the critical unmet need for antimicrobial resistance. Focus on high revenue segment - patients in hospitals.

Skyvor Medical develops AI-powered digital platforms (RecruitNavigator, ATOM EDC) to  accelerate the feasibility (protocol, site optimizations) and the data collection in clinical trials. Together with our data management services, we offer a turnkey solution for managing clinical trial data.

SOTIO is a biotech company building a diverse portfolio of oncology products through its own R&D, collaborations, in-licensing, investments, M&A. SOTIO is conducting multiple Phase I to III clinical trials targeting various types of cancer and has facilities in Europe and the US.

steerBIO GmbH is a boutique management consultancy for the VC, biotech and pharmaceutical industry. We support your complex R&D challenges associated with modern drug development and medical launch by integrating deep knowledge, honest analysis and strategic thinking in a co-creative approach.

Swiss Rockets is dedicated to developing groundbreaking medicines that transform the treatment of cancer, infectious diseases, and autoimmune disorders – advancing more effective, equitable, and accessible healthcare for patients worldwide.

Synendos is a clinical stage neuroscience company developing potentially breakthrough safe and effective therapies for neuropsychiatric and neurological disorders through the modulation of a new drug target in the endocannabinoid system enabling restoration of the natural functioning of the brain

TargImmune Therapeutics AG is a private Swiss-based biotechnology company focused on drug development using novel targeted onco-immunotherapies.

ten23 health, headquartered in Basel, Switzerland, was founded in 2021. We are the human-centric and sustainable strategic partner of choice for the pharmaceutical industry and biotech start-ups: we develop, manufacture, and test tomorrow’s medicines.

The Bloc Switzerland is a creative, full-service agency with 30 years of experience in impactful health communication. Our medical and creative teams craft corporate identities, websites, social media campaigns, brand brochures, and mode of action and corporate videos.

TOLREMO engages in the discovery and development of small molecule drugs that target novel drug resistance pathways in cancer therapy. TOLREMO’s vision is to meaningfully prolong the lives of cancer patients using its personalized anti-drug-resistance therapies.

Vaderis Therapeutics AG is a clinical stage biotech focussing on treatment of rare diseases caused by vascular malformations. The company was founded in 2019 in Basel, Switzerland, and closed a Series A investment of CHF 18.1 Mio in 2020.

Versameb AG is a privately held biotechnology company focusing on discovering and developing innovative RNA-based drugs for modulation of protein expression, including the ability to simultaneously influence several therapeutic targets, in a controlled manner, with one molecular construct.

Strategic, operational, business and finance advice to companies in the Life Sciences with focus on business planning and implementation (including strategies to secure financing, M&A and financial planning), clinical development/medical affairs and technical development/operations (CMC).

VISCHER’s life sciences practice group is advising over 60 private and public companies under Swiss law in: transactions & financing, partnering & licensing, know-how & innovation management; and regulatory, administrative procedures & compliance.

Ymmunobio AG is a preclinical stage biotechnology company developing first in class assets for the treatment of solid tumors.